- US FDA OK's expanded Eribitux use, Qiagen KRAS test
- Merck Serono points finger at UK oncologists for personalised meds lag
- Amgen links with Beta to take Vectibix to China
- Erbitux fails in Phase III EXPAND gastric cancer trial
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.